Sol-Gel Announces Receipt of Nasdaq Minimum Price Notice
May 28, 2024 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel Announces Receipt of Nasdaq Minimum Price Notice
Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates
May 20, 2024 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Sol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel
May 16, 2024 06:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel and Beimei Pharma annouce an Asset Purcase Agreement to commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and Israel
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
April 01, 2024 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments
March 13, 2024 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel Reports Full Year 2023 Financial Results and Corporate Developments
Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study
November 30, 2023 07:00 ET
|
Sol-Gel Technologies Ltd.
SGT-610 has “Orphan Drug” designation status in the U.S. and E.U. and “Breakthrough Therapy” designation status in the U.S., as potentially the first and only therapy aimed at preventing new BCCs in...
Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610
November 28, 2023 08:06 ET
|
Sol-Gel Technologies Ltd.
Event to be held on December 6, 2023 will focus on preventing basal cell carcinomas associated with Gorlin syndrome with a discussion of the disease burden, SGT-610 and the upcoming Phase 3 trial ...
Sol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 09, 2023 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) for Gorlin syndrome into Phase 3 testing in late 2023Gorlin Syndrome KOL event to be held on December 6, 2023Sol-Gel maintains...
Sol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
August 30, 2023 08:00 ET
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients...
Sol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 10, 2023 07:00 ET
|
Sol-Gel Technologies Ltd.
Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) for Gorlin syndrome into Phase 3 testing in late 2023 Sol-Gel’s recently announced agreement with Searchlight Pharma will...